News & Events
Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018 (opens in a new tab)
Baylor, Rebiotix Find Patient Microbiome Signatures That Differentiate Disease States (opens in a new tab)
Rebiotix Microbiome Health Index™ Data to be Presented at United European Gastroenterology Annual Conference (opens in a new tab)
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303 (opens in a new tab)
Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of Directors (opens in a new tab)
The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team (opens in a new tab)
Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease (opens in a new tab)
Microbiome Health Index™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018 (opens in a new tab)
Rebiotix Microbiota Restoration Therapy Products, Microbiome Health Index to Take Center Stage at Digestive Disease Week 2018 (opens in a new tab)
Rebiotix’s President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention (opens in a new tab)
Vedanta Biosciences to Present at Jefferies 2018 Global Healthcare Conference (opens in a new tab)
Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018 (opens in a new tab)
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates (opens in a new tab)
Rebiotix Presents Posters at ECCMID 2018 Highlighting Microbiome Health Index™ Value Potential and RBX2660 Phase 2 Clinical Program Data (opens in a new tab)
Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc. (opens in a new tab)
Rebiotix’s Lee Jones to Receive TRUST 2018 Courageous Women in Health Care Award (opens in a new tab)
Rebiotix’s Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe (opens in a new tab)
Rebiotix Develops Microbiome Health Index to Identify Indicators for Microbiome Restoration (opens in a new tab)
Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer (opens in a new tab)
Rebiotix Highlights 2017 Achievements and 2018 Objectives (opens in a new tab)